Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis

Peter P. Stanich, Einar Björnsson, Andrea A. Gossard, Felicity Enders, Roberta Jorgensen, Keith Lindor

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Background: Primary sclerosing cholangitis results in elevated but fluctuating serum alkaline phosphatase levels that occasionally return to normal. Aims: To investigate the frequency of normalization of alkaline phosphatase in newly diagnosed primary sclerosing cholangitis patients and the subsequent clinical outcomes. Methods: Records of newly diagnosed primary sclerosing cholangitis patients were examined retrospectively for laboratory values and clinical end points (cholangiocarcinoma, liver transplantation and death) within 10 years of diagnosis. Data from a recent prospective ursodeoxycholic acid treatment trial were also studied. Results: Eighty-seven patients met the inclusion criteria. Normalization of alkaline phosphatase was seen in 35 (40%) patients. Five (14%) patients with normalization reached an end point whereas 17 (33%) of the patients with persistent elevation reached an end point (P= 0.02). Ursodeoxycholic acid was used similarly by both groups. When the investigative criteria were applied to a prospective trial, there was again a significant relationship between normalization of alkaline phosphatase and survival in patients receiving ursodeoxycholic acid (P< 0.01) and the placebo group (P= 0.02). Conclusions: Serum alkaline phosphatase was found to normalize in a high proportion of newly diagnosed primary sclerosing cholangitis patients. This was significantly associated with a better prognosis in a retrospective cohort and when data from a prospective treatment trial was evaluated.

Original languageEnglish (US)
Pages (from-to)309-313
Number of pages5
JournalDigestive and Liver Disease
Volume43
Issue number4
DOIs
StatePublished - Apr 2011
Externally publishedYes

Fingerprint

Sclerosing Cholangitis
Alkaline Phosphatase
Ursodeoxycholic Acid
Cholangiocarcinoma
Serum
Liver Transplantation
Placebos
Survival
Therapeutics

Keywords

  • Alkaline phosphatase
  • Primary sclerosing cholangitis
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. / Stanich, Peter P.; Björnsson, Einar; Gossard, Andrea A.; Enders, Felicity; Jorgensen, Roberta; Lindor, Keith.

In: Digestive and Liver Disease, Vol. 43, No. 4, 04.2011, p. 309-313.

Research output: Contribution to journalArticle

Stanich, Peter P. ; Björnsson, Einar ; Gossard, Andrea A. ; Enders, Felicity ; Jorgensen, Roberta ; Lindor, Keith. / Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. In: Digestive and Liver Disease. 2011 ; Vol. 43, No. 4. pp. 309-313.
@article{751b97e19de64fc191616711eaaa49b3,
title = "Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis",
abstract = "Background: Primary sclerosing cholangitis results in elevated but fluctuating serum alkaline phosphatase levels that occasionally return to normal. Aims: To investigate the frequency of normalization of alkaline phosphatase in newly diagnosed primary sclerosing cholangitis patients and the subsequent clinical outcomes. Methods: Records of newly diagnosed primary sclerosing cholangitis patients were examined retrospectively for laboratory values and clinical end points (cholangiocarcinoma, liver transplantation and death) within 10 years of diagnosis. Data from a recent prospective ursodeoxycholic acid treatment trial were also studied. Results: Eighty-seven patients met the inclusion criteria. Normalization of alkaline phosphatase was seen in 35 (40{\%}) patients. Five (14{\%}) patients with normalization reached an end point whereas 17 (33{\%}) of the patients with persistent elevation reached an end point (P= 0.02). Ursodeoxycholic acid was used similarly by both groups. When the investigative criteria were applied to a prospective trial, there was again a significant relationship between normalization of alkaline phosphatase and survival in patients receiving ursodeoxycholic acid (P< 0.01) and the placebo group (P= 0.02). Conclusions: Serum alkaline phosphatase was found to normalize in a high proportion of newly diagnosed primary sclerosing cholangitis patients. This was significantly associated with a better prognosis in a retrospective cohort and when data from a prospective treatment trial was evaluated.",
keywords = "Alkaline phosphatase, Primary sclerosing cholangitis, Ursodeoxycholic acid",
author = "Stanich, {Peter P.} and Einar Bj{\"o}rnsson and Gossard, {Andrea A.} and Felicity Enders and Roberta Jorgensen and Keith Lindor",
year = "2011",
month = "4",
doi = "10.1016/j.dld.2010.12.008",
language = "English (US)",
volume = "43",
pages = "309--313",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis

AU - Stanich, Peter P.

AU - Björnsson, Einar

AU - Gossard, Andrea A.

AU - Enders, Felicity

AU - Jorgensen, Roberta

AU - Lindor, Keith

PY - 2011/4

Y1 - 2011/4

N2 - Background: Primary sclerosing cholangitis results in elevated but fluctuating serum alkaline phosphatase levels that occasionally return to normal. Aims: To investigate the frequency of normalization of alkaline phosphatase in newly diagnosed primary sclerosing cholangitis patients and the subsequent clinical outcomes. Methods: Records of newly diagnosed primary sclerosing cholangitis patients were examined retrospectively for laboratory values and clinical end points (cholangiocarcinoma, liver transplantation and death) within 10 years of diagnosis. Data from a recent prospective ursodeoxycholic acid treatment trial were also studied. Results: Eighty-seven patients met the inclusion criteria. Normalization of alkaline phosphatase was seen in 35 (40%) patients. Five (14%) patients with normalization reached an end point whereas 17 (33%) of the patients with persistent elevation reached an end point (P= 0.02). Ursodeoxycholic acid was used similarly by both groups. When the investigative criteria were applied to a prospective trial, there was again a significant relationship between normalization of alkaline phosphatase and survival in patients receiving ursodeoxycholic acid (P< 0.01) and the placebo group (P= 0.02). Conclusions: Serum alkaline phosphatase was found to normalize in a high proportion of newly diagnosed primary sclerosing cholangitis patients. This was significantly associated with a better prognosis in a retrospective cohort and when data from a prospective treatment trial was evaluated.

AB - Background: Primary sclerosing cholangitis results in elevated but fluctuating serum alkaline phosphatase levels that occasionally return to normal. Aims: To investigate the frequency of normalization of alkaline phosphatase in newly diagnosed primary sclerosing cholangitis patients and the subsequent clinical outcomes. Methods: Records of newly diagnosed primary sclerosing cholangitis patients were examined retrospectively for laboratory values and clinical end points (cholangiocarcinoma, liver transplantation and death) within 10 years of diagnosis. Data from a recent prospective ursodeoxycholic acid treatment trial were also studied. Results: Eighty-seven patients met the inclusion criteria. Normalization of alkaline phosphatase was seen in 35 (40%) patients. Five (14%) patients with normalization reached an end point whereas 17 (33%) of the patients with persistent elevation reached an end point (P= 0.02). Ursodeoxycholic acid was used similarly by both groups. When the investigative criteria were applied to a prospective trial, there was again a significant relationship between normalization of alkaline phosphatase and survival in patients receiving ursodeoxycholic acid (P< 0.01) and the placebo group (P= 0.02). Conclusions: Serum alkaline phosphatase was found to normalize in a high proportion of newly diagnosed primary sclerosing cholangitis patients. This was significantly associated with a better prognosis in a retrospective cohort and when data from a prospective treatment trial was evaluated.

KW - Alkaline phosphatase

KW - Primary sclerosing cholangitis

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=79952194307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952194307&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2010.12.008

DO - 10.1016/j.dld.2010.12.008

M3 - Article

C2 - 21251891

AN - SCOPUS:79952194307

VL - 43

SP - 309

EP - 313

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 4

ER -